RNA vs ENTX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 04, 2026

RNA

49.0
AI Score
VS
RNA Wins

ENTX

45.2
AI Score

Investment Advisor Scores

RNA

49score
Recommendation
HOLD

ENTX

45score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric RNA ENTX Winner
Net Income -36.82M -10.82M ENTX
Operating Income -39.90M -8.10M ENTX
ROE -17.2% -148.9% RNA
ROA -13.1% -55.5% RNA
Total Assets 280.51M 19.48M RNA
Cash 72.33M 11.31M RNA
Current Ratio 8.73 8.98 ENTX
Free Cash Flow -37.20M -6.56M ENTX

Relative Price Performance (Last 90 Days)

RNA 1M: +2.7% · 3M: -35.4% ENTX 1M: +29.3% · 3M: +12.2%

Current Technical Phase

RNA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -17.8%), weak momentum, RSI 39

RSI (14): 39.5 · Price: $7.96

ENTX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 60

RSI (14): 60.1 · Price: $3.22

Fundamentals Snapshot

Metric RNA ENTX
Market Cap — —
Forward P/E -1.3 -7.6
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.2% -1.0%
Gross Margin -0.6% —
Operating Margin -7.5% 0.0%
EPS -5.44 -0.40
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, RNA is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.